Autori: Bravetti C

Filtra

Data

Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study

Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function

Neurological assessment of newborns with spinal muscular atrophy identified through neonatal screening

Body mass index in type 2 spinal muscular atrophy: a longitudinal study

Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy

Type I SMA “new natural history”: long-term data in nusinersen-treated patients

Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data

Torna in alto